32nd EURORDIS Round Table of Companies Workshop

The impact of the EU regulatory network strategy 2020-2025 on the development of orphan medicines


20-21 October 2021

14.00-18.00 CET


Workshop Description

The European Medicines Agencies Network Strategy to 2025 and  Regulatory Science Strategy to 2025 are forming a comprehensive approach to plan and prepare for the future. This includes preparing the EU regulatory network for the next generation of regulatory activities. In order to do this, four EMA Task Forces have been created on: Digital Business Transformation, Data Analytics and Methods, Regulatory Science & Innovation and Clinical Studies and Manufacturing.

The 32nd EURORDIS Round Table of Companies Workshop will place a strong emphasis on exploring and discussing elements of these task forces, and their impact and importance for developers of rare disease treatments.

This is your opportunity to join us to discuss and gain insights into new methods to analyse data, new sources of data and changes in the way new Clinical Trials are conducted.


This workshop will provide valuable information to its participants with the following objectives:

  • Get insights into the future of the regulatory strategy for data acquisition and analysis
  • Learn about the new EMA task forces established to prepare the regulatory network for modern methods
  • Understand how all stakeholders can prepare and plan for the future and benefit from the changes
  • Learn how clinical trials will be conducted in the next 20 years with the revision of the ICHE6
  • Understand how patients will benefit from shorter and more innovative clinical trials, more robust HTA assessments, new digital solutions to measure efficacy and how more real world evidence data will help to reduce risk and make decisions more certain


You can download the draft programme here.


Registration for the 32nd ERTC Workshop will open at the beginning of September 2021.

ERTC members will receive an email with the link to register

For any other registration category please contact Martina Bergna.

The event is recommended for the following target audience:

  • Pharmaceutical and biotech representatives with expertise in:
    • Regulatory Affairs
    • Research and Development
    • Health Technology Assessment (HTA) and Market Access
    • Medical Affairs and Clinical Trials
  • Clinical Research Organisations (CROs)
  • Academic/Medical institutions and patient groups involved in designing Clinical Trials
  • EURORDIS Summer School Alumni
  • European Medicines Agency and European Commission
  • Health Technology Assessment Agencies
  • European Reference Networks (ERNs)


Please send any questions concerning registration to Martina Bergna

We look forward to welcoming you to the EURORDIS Round Table of Companies.

La voce dei malati rari in EuropaEURORDIS Rare Diseases International, la voce internazionale dei malati rariRare Disease International RareConnect è un'iniziativa di EURORDIS che mette in contatto malati, famiglie ed esperti per condividere esperienze in un forum multilingua e moderato RareConnect Il Programma Rare Barometer è un’iniziativa di EURORDIS volta a condurre indagini con l’obiettivo di trasformare le esperienze delle persone affette da malattie rare in cifre e fatti che possono essere condivisi con i decisori politici.Rare Barometer La Giornata delle Malattie Rare, una campagna di sensibilizzazione internazionale che si svolge l'ultimo giorno di febbraio di ogni anno.Rare Disease Day La Conferenza Europea biennale sulle Malattie Rare è il più grande incontro di soggetti interessati al tema delle Malattie Rare in Europa. L'ECRD è un'iniziativa di EURORDISEuropean Conference on Rare Diseases